Trial Profile
A multicenter clinical trial comparing vosaroxin plus decitabine and vosaroxin plus cytarabine to the 7+3 regimen in patients with AML
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Vosaroxin (Primary) ; Cytarabine; Decitabine
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 17 Jun 2016 New trial record